Intraperitoneal chromic phosphate in ovarian cancer: risks and benefits.
Between March 1977 and December 1985, 59 patients were treated with intraperitoneal chromic phosphate at The University of Alabama Birmingham Hospitals and its affiliates. Twenty-seven patients received primary adjuvant therapy. Thirty-two patients were treated "secondarily" after tumor recurrence or after a "positive" second-look laparotomy. Associated morbidity was noted to be 12% with reoperation required in 7%. Early stage and grade tumors demonstrate a good prognosis. Little, if any, benefit was demonstrated in "secondary" therapy of advanced stage and grade tumors.
Potter
M E
ME
University of Alabama, Department of Obstetrics and Gynecology, Birmingham 35294.
Partridge
E E
EE
Shingleton
H M
HM
Soong
S J
SJ
Kim
R Y
RY
Hatch
K D
KD
Austin
J M
JM
D002857:Chromium / Q000008:administration & dosage* / Q000627:therapeutic use; D017608:Chromium Compounds; D005260:Female; D006801:Humans; D007322:Instillation, Drug; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D010529:Peritoneal Cavity; D010710:Phosphates / Q000008:administration & dosage* / Q000627:therapeutic use; D010761:Phosphorus Radioisotopes / Q000008:administration & dosage* / Q000627:therapeutic use
D017608:Chromium Compounds; D010710:Phosphates; D010761:Phosphorus Radioisotopes; D002857:Chromium; C509369:chromic phosphate